Ottawa | The federal government asked vaccine manufacturers in Canada to come and produce their pots to avoid the import problems we are currently facing, but everyone except Novavox refused.
“They have all concluded that bio-manufacturing capabilities are too limited to justify the investment of capital and expertise to start production in Canada,” Supply Minister Anita Anand told a parliamentary committee on Thursday.
Meanwhile, Moderna reduced its deliveries this week and “the week of February 22 will also be affected,” said Major General Fortin, who handles pottery distribution.
He acknowledged on Thursday that there was “no way to say for sure” that Pfizer and Moderna would be available to Canada in the coming weeks.
This is because supply contracts do not even give for weekly or monthly deliveries, but for the entire quarter, Minister Anand revealed.
So there is nothing to keep deliveries as volatile as Modena and Pfizer did last month.
Like Pfizer and Moderna, the country’s next licensed vaccine, AstraZeneca, refuses to be produced here because Canada does not support the “required production level”. “Anand.
In India, for example, the company has teamed up with the Serum Institute, the world’s largest vaccine manufacturer, to produce one billion doses.
Half a dozen factories
There are half a dozen vaccine factories in Canada that can produce nearly a billion doses a year.
But they do not all have the same technologies and production platforms, “said Innovation Minister Franకోois-Philippe Champagne,” not all vaccines are the same.
Minister Anand told CEO Stanley Erk Bloomberg a year ago that Novavox, the only company to accept the offer, had no production capacity. It has therefore developed partnerships with seven different countries so that they can produce their own doses.
For Erk, his vaccine is about making sure it is constantly being produced nationwide, so Canadians can be bitten every year if needed, as in the case of the flu.